KR20150065176A - 에르타페넴 중간체의 제조법 - Google Patents
에르타페넴 중간체의 제조법 Download PDFInfo
- Publication number
- KR20150065176A KR20150065176A KR1020157009049A KR20157009049A KR20150065176A KR 20150065176 A KR20150065176 A KR 20150065176A KR 1020157009049 A KR1020157009049 A KR 1020157009049A KR 20157009049 A KR20157009049 A KR 20157009049A KR 20150065176 A KR20150065176 A KR 20150065176A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- salt
- solvate
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 55
- 239000000543 intermediate Substances 0.000 title abstract description 23
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 title description 3
- 229960002770 ertapenem Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 341
- 238000000034 method Methods 0.000 claims abstract description 98
- 150000003839 salts Chemical class 0.000 claims abstract description 83
- 230000008569 process Effects 0.000 claims abstract description 40
- 239000012453 solvate Substances 0.000 claims description 70
- -1 p-substituted benzyl Chemical group 0.000 claims description 31
- 125000006239 protecting group Chemical group 0.000 claims description 25
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 23
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 10
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 150000004820 halides Chemical class 0.000 claims description 8
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 3
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 abstract description 5
- 229940088710 antibiotic agent Drugs 0.000 abstract description 4
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 abstract 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 81
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 34
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 239000002904 solvent Substances 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 18
- 238000002955 isolation Methods 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- VOLRSQPSJGXRNJ-UHFFFAOYSA-N 4-nitrobenzyl bromide Chemical compound [O-][N+](=O)C1=CC=C(CBr)C=C1 VOLRSQPSJGXRNJ-UHFFFAOYSA-N 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 239000013078 crystal Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000010899 nucleation Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 10
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 9
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- QCOGKXLOEWLIDC-UHFFFAOYSA-N N-methylbutylamine Chemical compound CCCCNC QCOGKXLOEWLIDC-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 150000001649 bromium compounds Chemical class 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 5
- 0 C[C@]([C@]([C@@]([C@@]1C)N2C(C(O*)=O)=C1S[C@@](C[C@]1C(Nc3cc(C(O*)=O)ccc3)=O)CN1C(O*)=O)C2=O)O Chemical compound C[C@]([C@]([C@@]([C@@]1C)N2C(C(O*)=O)=C1S[C@@](C[C@]1C(Nc3cc(C(O*)=O)ccc3)=O)CN1C(O*)=O)C2=O)O 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000010 aprotic solvent Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- SDGKUVSVPIIUCF-KNVOCYPGSA-N (2r,6s)-2,6-dimethylpiperidine Chemical compound C[C@H]1CCC[C@@H](C)N1 SDGKUVSVPIIUCF-KNVOCYPGSA-N 0.000 description 4
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 4
- 150000008052 alkyl sulfonates Chemical class 0.000 description 4
- 125000005228 aryl sulfonate group Chemical group 0.000 description 4
- 239000002178 crystalline material Substances 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- XHFGWHUWQXTGAT-UHFFFAOYSA-N n-methylpropan-2-amine Chemical compound CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 4
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
- 229910017488 Cu K Inorganic materials 0.000 description 3
- 229910017541 Cu-K Inorganic materials 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- ODVBBZFQPGORMJ-UHFFFAOYSA-N 4-nitrobenzylamine Chemical compound NCC1=CC=C([N+]([O-])=O)C=C1 ODVBBZFQPGORMJ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- PRRFKAHPVHOSNQ-PYISTNOASA-N C[C@H]([C@H]([C@@H]([C@H]1C)N2C(C(OCc(cc3)ccc3[N+]([O-])=O)=O)=C1S[C@@H](C[C@H]1C(Nc3cc(C(OCc(cc4)ccc4[N+]([O-])=O)=O)ccc3)=O)CN1C(OCc(cc1)ccc1[N+]([O-])=O)=O)C2=O)O Chemical compound C[C@H]([C@H]([C@@H]([C@H]1C)N2C(C(OCc(cc3)ccc3[N+]([O-])=O)=O)=C1S[C@@H](C[C@H]1C(Nc3cc(C(OCc(cc4)ccc4[N+]([O-])=O)=O)ccc3)=O)CN1C(OCc(cc1)ccc1[N+]([O-])=O)=O)C2=O)O PRRFKAHPVHOSNQ-PYISTNOASA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- GOQPEYBIDGQAAI-UYOWANHXSA-N (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]-6-(1-hydroxyethyl)-4-methyl-7-oxo-4-sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C(=O)(O)C=1C=C(C=CC=1)NC(=O)[C@@H]1C[C@H](CN1)C1=C(N2C([C@@H]([C@H]2[C@]1(C)S)C(C)O)=O)C(=O)O GOQPEYBIDGQAAI-UYOWANHXSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- NBAWJYARJRYDME-UHFFFAOYSA-O CC(C(C(C1)N2C(C(O)=O)=C1SC(C1)C[NH2+]C1C(Nc1cc(C(O)=O)ccc1)=O)C2=O)O Chemical compound CC(C(C(C1)N2C(C(O)=O)=C1SC(C1)C[NH2+]C1C(Nc1cc(C(O)=O)ccc1)=O)C2=O)O NBAWJYARJRYDME-UHFFFAOYSA-O 0.000 description 1
- JUZNIMUFDBIJCM-UHFFFAOYSA-O CC(C(C(C1C)N2C(C(O)=O)=C1SC(C1)C[NH2+]C1C(Nc1cccc(C(O)=O)c1)=O)C2=O)O Chemical compound CC(C(C(C1C)N2C(C(O)=O)=C1SC(C1)C[NH2+]C1C(Nc1cccc(C(O)=O)c1)=O)C2=O)O JUZNIMUFDBIJCM-UHFFFAOYSA-O 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- ICTAZHZJEOVXOW-UHFFFAOYSA-N platinum vanadium Chemical compound [V].[Pt].[Pt].[Pt] ICTAZHZJEOVXOW-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/02—Preparation
- C07D477/06—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
- C07D477/08—Modification of a carboxyl group directly attached in position 2, e.g. esterification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12188351 | 2012-10-12 | ||
| EP12188351.6 | 2012-10-12 | ||
| PCT/EP2013/071252 WO2014057079A1 (en) | 2012-10-12 | 2013-10-11 | Preparation of ertapenem intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150065176A true KR20150065176A (ko) | 2015-06-12 |
Family
ID=47022553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157009049A Withdrawn KR20150065176A (ko) | 2012-10-12 | 2013-10-11 | 에르타페넴 중간체의 제조법 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9546171B2 (enExample) |
| EP (1) | EP2906561A1 (enExample) |
| JP (1) | JP2015533142A (enExample) |
| KR (1) | KR20150065176A (enExample) |
| CN (1) | CN104703986A (enExample) |
| AU (1) | AU2013328585A1 (enExample) |
| CA (1) | CA2887098A1 (enExample) |
| IN (1) | IN2015DN02513A (enExample) |
| WO (1) | WO2014057079A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2906561A1 (en) * | 2012-10-12 | 2015-08-19 | Sandoz AG | Preparation of ertapenem intermediates |
| CN113880839A (zh) * | 2021-11-01 | 2022-01-04 | 石药集团中诺药业（石家庄）有限公司 | 一种厄他培南钠粗品的合成新方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9202298D0 (en) * | 1992-02-04 | 1992-03-18 | Ici Plc | Antibiotic compounds |
| AR008255A1 (es) | 1996-07-12 | 1999-12-29 | Merck & Co Inc | Procedimiento para sintetizar antibioticos de carbapenem |
| CA2293835C (en) | 1997-06-16 | 2003-09-16 | John M. Williams | Stabilized carbapenem intermediates and synthetic use |
| US5872250A (en) * | 1997-07-30 | 1999-02-16 | Merck & Co., Inc. | Process for synthesizing carbapenem antibiotics |
| JP2005508321A (ja) | 2001-09-26 | 2005-03-31 | メルク エンド カムパニー インコーポレーテッド | 結晶形態のエルタペネムナトリウム |
| CN100457760C (zh) * | 2005-10-20 | 2009-02-04 | 上海交通大学 | 尔他培南钠盐的制备方法 |
| US8293894B2 (en) | 2006-11-20 | 2012-10-23 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of carbapenem antibiotic |
| RU2575979C2 (ru) * | 2009-04-30 | 2016-02-27 | СиЭсПиСи ЧЖУНЦИ ФАРМАСЬЮТИКАЛ ТЕКНОЛОДЖИ (ШИЦЗЯЧЖУАН)КО., ЛТД. | Способ получения промежуточного соединения эртапенема |
| US20110288289A1 (en) * | 2010-05-19 | 2011-11-24 | Savior Lifetec Corporation | Preparation of Carbapenem Intermediate and Their Use |
| US8729260B2 (en) * | 2010-05-19 | 2014-05-20 | Savior Lifetec Corporation | Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem |
| KR20120007331A (ko) | 2010-07-14 | 2012-01-20 | 주식회사 경보제약 | 카르바페넴계 화합물들의 개선된 제조방법 |
| CN101935321A (zh) * | 2010-07-20 | 2011-01-05 | 深圳市海滨制药有限公司 | 1β甲基碳青霉烯类抗生素的合成方法 |
| CN102731502B (zh) | 2011-04-13 | 2016-08-03 | 石药集团中奇制药技术（石家庄）有限公司 | 一种碳青霉烯抗生素的制备方法 |
| CN102351861A (zh) * | 2011-08-16 | 2012-02-15 | 湖南欧亚生物有限公司 | 一种厄他培南的工业化制备方法 |
| CN102432611B (zh) * | 2011-11-09 | 2013-11-20 | 上海希迈医药科技有限公司 | 一种双保护厄他培南结晶体及其制备方法 |
| CN102731508A (zh) * | 2012-07-03 | 2012-10-17 | 浙江海翔川南药业有限公司 | 一种晶体形式的厄他培南中间体及其制备方法和应用 |
| EP2906561A1 (en) * | 2012-10-12 | 2015-08-19 | Sandoz AG | Preparation of ertapenem intermediates |
-
2013
- 2013-10-11 EP EP13774444.7A patent/EP2906561A1/en not_active Withdrawn
- 2013-10-11 IN IN2513DEN2015 patent/IN2015DN02513A/en unknown
- 2013-10-11 AU AU2013328585A patent/AU2013328585A1/en not_active Abandoned
- 2013-10-11 JP JP2015536143A patent/JP2015533142A/ja active Pending
- 2013-10-11 WO PCT/EP2013/071252 patent/WO2014057079A1/en not_active Ceased
- 2013-10-11 KR KR1020157009049A patent/KR20150065176A/ko not_active Withdrawn
- 2013-10-11 CN CN201380053067.5A patent/CN104703986A/zh active Pending
- 2013-10-11 CA CA2887098A patent/CA2887098A1/en not_active Abandoned
- 2013-10-11 US US14/434,550 patent/US9546171B2/en not_active Expired - Fee Related
-
2017
- 2017-01-17 US US15/407,741 patent/US20170166570A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150274732A1 (en) | 2015-10-01 |
| IN2015DN02513A (enExample) | 2015-09-11 |
| US20170166570A1 (en) | 2017-06-15 |
| CN104703986A (zh) | 2015-06-10 |
| JP2015533142A (ja) | 2015-11-19 |
| EP2906561A1 (en) | 2015-08-19 |
| US9546171B2 (en) | 2017-01-17 |
| WO2014057079A1 (en) | 2014-04-17 |
| CA2887098A1 (en) | 2014-04-17 |
| AU2013328585A1 (en) | 2015-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2388261B1 (en) | Improved process for the preparation of carbapenem using carbapenem intermediates and recovery of carbapenem | |
| JP2005508321A (ja) | 結晶形態のエルタペネムナトリウム | |
| EP1992626A1 (en) | Process for the preparation of moxifloxacin hydrochloride | |
| CN101935321A (zh) | 1β甲基碳青霉烯类抗生素的合成方法 | |
| KR101491871B1 (ko) | 아연 분말을 이용한 메로페넴의 개선된 제조방법 | |
| US9388184B2 (en) | Intermediate of Ertapenem, a composition comprising the same and preparation methods thereof | |
| WO2011141847A1 (en) | An improved process for the preparation of meropenem | |
| EP2401278A1 (en) | An improved process for the preparation of carbapenem antibiotic | |
| JP4100908B2 (ja) | 塩基性抗生物質・無機酸塩の製造法およびシュウ酸塩中間体 | |
| KR20150065176A (ko) | 에르타페넴 중간체의 제조법 | |
| EP1776365B1 (en) | Meropenem intermediate in crystalline form | |
| US20020095034A1 (en) | Imipenem production process | |
| US20110288289A1 (en) | Preparation of Carbapenem Intermediate and Their Use | |
| CN101311178B (zh) | 一种化合物帕尼培南的合成方法 | |
| US20040242874A1 (en) | Process for synthesizing beta-lactamase inhibitor intermediates | |
| KR101050976B1 (ko) | 카바페넴계 항생제의 합성 중간체의 산부가염 및 그의 제조방법 | |
| KR20120007331A (ko) | 카르바페넴계 화합물들의 개선된 제조방법 | |
| WO2006018807A1 (en) | Crystalline forms of cefdinir | |
| CN106083859B (zh) | 一种亚胺培南一水合物晶体的制备方法 | |
| KR20070104594A (ko) | 카르바페넴 유도체 및 이에 대한 결정성 중간체의 제조방법 | |
| US20030045709A1 (en) | Crystalline forms of carbapenem intermediates | |
| KR101028689B1 (ko) | 신규한 결정성 3-머캅토-1-(아세트이미도일)피롤리딘유도체 및 그의 제조방법 | |
| CN120097983A (zh) | 百纳培南的制备方法 | |
| KR20040035025A (ko) | 옥사디아졸고리를 포함하는 피롤리딘 치환체를 가지는1-베타메틸카바페넴 유도체 및 그 제조방법 | |
| WO2017046131A1 (en) | Processes for preparing solid state forms of dolutegravir sodium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150408 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |